Innate Pharma SA
Sandrine Maignan - Arrufat has extensive experience in laboratory research, specifically in immunohistochemistry, cytogenetics, and pathology. Currently serving as a Technicienne R&D in Immuno-histochimie at Innate Pharma since October 2017, responsibilities include cell culture and antigen expression verification through flow cytometry. Previous roles encompass positions at the Institut Paoli-Calmettes and INSERM, focusing on cell cultures and gene expression studies, as well as significant contributions in experimental pathology at the Institut Curie, where techniques such as tissue microarrays and antibody development were employed. With a strong foundation in molecular biology techniques and a BTS in Biochemistry, Sandrine possesses a comprehensive skill set in genetic diagnostics and laboratory techniques.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.